UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Recruiting
18 years - 64 years
All
Phase 1
5 participants needed

Brief description of study

Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).
 



Detailed description of study

The main purpose of this study is to test the safety of an oral drug, ibrutinib, added to the standard lymphoma treatment.
 We will also study whether ibrutinib has a helpful effect against HIV and other viruses in our bodies that can cause lymphoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-Hodgkin lymphoma,Diffuse Large B-cell Lymphoma,HIV+,
  • Age: 18 years - 64 years
  • Gender: All

  1. Participants must have documented CD20 positive or negative diffuse large B-cell lymphoma (DLBCL).
  2. Stage II-IV disease.
  3. Documentation of HIV diagnosis.
  4.  Be 18–64 yrs of age.

Updated on 19 Feb 2024. Study ID: 828995

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.